NR3C1 and glioblastoma: Currently, there is a phase 1 clinical trial that is currently recruiting patients, in order to determine the best dose as well as the side effects of engineered natural killer (NK) cells TGFBR2-KO and NR3C1 (cord blood [CB]-NK-TGF-betaR2-/NR3C1-) in treating patients with recurrent glioblastoma (NCT04991870).